Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Director | June 03, 2026 | June 05, 2026 |
| PERNIX THERAPEUTICS HOLDINGS, INC.PTX · Entity 161208 | Director | May 22, 2018 | May 23, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 101,109 |
Reported balance
After 2026-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 11,610 · Balance 101,109 F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.15 · Expires 2036-06-03 | Direct | 16,999 |
Reported balance
After 2026-06-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-03 · Grant · Acquired 16,999 · Balance 16,999 F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
PERNIX THERAPEUTICS HOLDINGS, INC.
Report date May 22, 2018 · Filed May 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.63 · Expires 2028-05-21 | Direct | 25,000 |
Reported balance
After 2018-05-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-22 · Grant · Acquired 25,000 · Balance 25,000 F1: The stock option vests in four equal annual installments of 6,250 shares over a four-year period, with the first installment vesting on May 22, 2019, which is the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in four equal annual installments of 6,250 shares over a four-year period, with the first installment vesting on May 22, 2019, which is the one-year anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 5, 2026 20:27 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 16,999 | $0.00 Strike: $16.15 | $0.00 |
DisclosureSEC source: 0001236183-26-000002 · primarydocument.xml · derivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,999 Underlying: Ordinary Shares · 16,999 shares Expires 2036-06-03 F2 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:27 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 11,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001236183-26-000002 · primarydocument.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,109 F1 · security: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 20:54 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,945 | $15.77 | $46,444.71 |
DisclosureSEC source: 0001236183-26-000001 · primarydocument.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,499 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:21 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 16,697 | $0.00 Strike: $16.72 | $0.00 |
DisclosureSEC source: 0001562180-25-004562 · primarydocument.xml · derivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,697 Underlying: Ordinary Shares · 16,697 shares Expires 2035-06-04 F2 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:21 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 11,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004562 · primarydocument.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,444 F1 · security: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders. Read SEC document |
| June 03, 2025 Filed Jun 4, 2025 20:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 999 | $17.31 | $17,297.29 |
DisclosureSEC source: 0001562180-25-004440 · primarydocument.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,229 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.1025 USD to $17.50 USD; the price reported above reflects the weighted average sale price. F3 · balance_after: Amended total to correct prior mathematical error. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 21:42 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 6,229 | $0.00 Strike: $23.13 | $0.00 |
DisclosureSEC source: 0001562180-24-004758 · primarydocument.xml · derivative · entry 3 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,229 Underlying: Ordinary Shares · 6,229 shares Expires 2034-06-04 F3 · derivative.exercise_date: Options to buy 6,229 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 21:42 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Units | 4,053 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-004758 · primarydocument.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,192 F2 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 21:42 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 964 | $23.89 | $23,025.24 |
DisclosureSEC source: 0001562180-24-004758 · primarydocument.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,175 F1 · price: This transaction was executed in multiple trades at prices ranging from $23.75 USD to $24.00 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:04 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 6,277 | $0.00 Strike: $48.66 | $0.00 |
DisclosureSEC source: 0001562180-23-005013 · primarydocument.xml · derivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,277 Underlying: Ordinary Shares · 6,277 shares Expires 2033-06-06 F2 · derivative.exercise_date: Options to buy 6,277 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:04 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Units | 3,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005013 · primarydocument.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,139 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:09 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 4,350 | $0.00 Strike: $77.25 | $0.00 |
DisclosureSEC source: 0001645113-22-000051 · wf-form4_165489173935006.xml · derivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,350 Underlying: Ordinary Shares · 4,350 shares Expires 2032-06-08 F2 · derivative.exercise_date: Options to buy 4,350 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2023 annual general meeting of shareholders. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:09 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Units | 2,427 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-22-000051 · wf-form4_165489173935006.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,286 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2023 annual general meeting of shareholders. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 20:39 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 1,000 | $0.00 Strike: $31.45 | $0.00 |
DisclosureSEC source: 0001645113-21-000099 · wf-form4_162828232363128.xml · derivative · entry 3 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,345 Underlying: Ordinary Shares · 1,000 shares Expires 2028-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 20:39 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,000 | $152.50 | $152,500.00 |
DisclosureSEC source: 0001645113-21-000099 · wf-form4_162828232363128.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,859 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 20:39 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 1,000 | $31.45 | $31,450.00 |
DisclosureSEC source: 0001645113-21-000099 · wf-form4_162828232363128.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 21:23 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 1,000 | $0.00 Strike: $31.45 | $0.00 |
DisclosureSEC source: 0001645113-21-000081 · wf-form4_162577940551935.xml · derivative · entry 3 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,345 Underlying: Ordinary Shares · 1,000 shares Expires 2028-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 21:23 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,000 | $183.54 | $183,540.00 |
DisclosureSEC source: 0001645113-21-000081 · wf-form4_162577940551935.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,859 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 21:23 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 1,000 | $31.45 | $31,450.00 |
DisclosureSEC source: 0001645113-21-000081 · wf-form4_162577940551935.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:18 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 1,499 | $0.00 Strike: $211.89 | $0.00 |
DisclosureSEC source: 0001645113-21-000074 · wf-form4_162344271604748.xml · derivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,499 Underlying: Ordinary Shares · 1,499 shares Expires 2031-06-09 F2 · derivative.exercise_date: Options to buy 1,499 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2022 annual general meeting of shareholders. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:18 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Units | 814 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000074 · wf-form4_162344271604748.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,859 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2022 annual general meeting of shareholders. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 20:49 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 1,000 | $0.00 Strike: $31.45 | $0.00 |
DisclosureSEC source: 0001645113-21-000070 · wf-form4_162318536093579.xml · derivative · entry 3 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,345 Underlying: Ordinary Shares · 1,000 shares Expires 2028-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 20:49 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,000 | $204.55 | $204,550.00 |
DisclosureSEC source: 0001645113-21-000070 · wf-form4_162318536093579.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,045 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 20:49 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 1,000 | $31.45 | $31,450.00 |
DisclosureSEC source: 0001645113-21-000070 · wf-form4_162318536093579.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2021 Filed May 6, 2021 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 1,000 | $0.00 Strike: $31.45 | $0.00 |
DisclosureSEC source: 0001645113-21-000064 · wf-form4_162033208722403.xml · derivative · entry 3 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,345 Underlying: Ordinary Shares · 1,000 shares Expires 2028-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| May 05, 2021 Filed May 6, 2021 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,000 | $199.67 | $199,670.00 |
DisclosureSEC source: 0001645113-21-000064 · wf-form4_162033208722403.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,045 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| May 05, 2021 Filed May 6, 2021 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 1,000 | $31.45 | $31,450.00 |
DisclosureSEC source: 0001645113-21-000064 · wf-form4_162033208722403.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:00 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 6,000 | $0.00 Strike: $31.45 | $0.00 |
DisclosureSEC source: 0001645113-21-000054 · wf-form4_161852400582979.xml · derivative · entry 4 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,345 Underlying: Ordinary Shares · 6,000 shares Expires 2028-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,500 | $200.00 | $500,000.00 |
DisclosureSEC source: 0001645113-21-000054 · wf-form4_161852400582979.xml · nonDerivative · entry 3 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,045 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,500 | $198.01 | $693,035.00 |
DisclosureSEC source: 0001645113-21-000054 · wf-form4_161852400582979.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,545 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:00 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 6,000 | $31.45 | $188,700.00 |
DisclosureSEC source: 0001645113-21-000054 · wf-form4_161852400582979.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:27 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 7,392 | $0.00 Strike: $7.48 | $0.00 |
DisclosureSEC source: 0001645113-20-000137 · wf-form4_160029160768385.xml · derivative · entry 9 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,392 shares Expires 2024-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:27 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 2,173 | $0.00 Strike: $7.48 | $0.00 |
DisclosureSEC source: 0001645113-20-000137 · wf-form4_160029160768385.xml · derivative · entry 8 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,173 shares Expires 2024-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:27 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 7,392 | $100.00 | $739,200.00 |
DisclosureSEC source: 0001645113-20-000137 · wf-form4_160029160768385.xml · nonDerivative · entry 6 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,045 F1 · price: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:27 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 7,392 | $7.48 | $55,292.16 |
DisclosureSEC source: 0001645113-20-000137 · wf-form4_160029160768385.xml · nonDerivative · entry 5 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:27 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,173 | $100.00 | $217,300.00 |
DisclosureSEC source: 0001645113-20-000137 · wf-form4_160029160768385.xml · nonDerivative · entry 4 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,045 F1 · price: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:27 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 2,173 | $7.48 | $16,254.04 |
DisclosureSEC source: 0001645113-20-000137 · wf-form4_160029160768385.xml · nonDerivative · entry 3 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 21:27 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 10,000 | $0.00 Strike: $7.48 | $0.00 |
DisclosureSEC source: 0001645113-20-000137 · wf-form4_160029160768385.xml · derivative · entry 7 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,173 Underlying: Ordinary Shares · 10,000 shares Expires 2024-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 21:27 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 10,000 | $95.00 | $950,000.00 |
DisclosureSEC source: 0001645113-20-000137 · wf-form4_160029160768385.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,045 F1 · price: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 21:27 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 10,000 | $7.48 | $74,800.00 |
DisclosureSEC source: 0001645113-20-000137 · wf-form4_160029160768385.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 10,000 | $0.00 Strike: $7.48 | $0.00 |
DisclosureSEC source: 0001645113-20-000134 · wf-form4_159985533001922.xml · derivative · entry 7 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,173 Underlying: Ordinary Shares · 10,000 shares Expires 2024-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 10,000 | $90.00 | $900,000.00 |
DisclosureSEC source: 0001645113-20-000134 · wf-form4_159985533001922.xml · nonDerivative · entry 5 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,045 F2 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. F3 · balance_after: Fully vested as of the date hereof. Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 10,000 | $7.48 | $74,800.00 |
DisclosureSEC source: 0001645113-20-000134 · wf-form4_159985533001922.xml · nonDerivative · entry 4 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 9,114 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001645113-20-000134 · wf-form4_159985533001922.xml · derivative · entry 6 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,114 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 100 | $86.06 | $8,606.00 |
DisclosureSEC source: 0001645113-20-000134 · wf-form4_159985533001922.xml · nonDerivative · entry 3 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,045 F2 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. F3 · balance_after: Fully vested as of the date hereof. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 9,014 | $85.39 | $769,687.43 |
DisclosureSEC source: 0001645113-20-000134 · wf-form4_159985533001922.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,145 F1 · shares: On September 9, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung, Mr. Leung sold 9,014 shares in multiple trades at prices ranging from $85.00 to $85.92. The price reported above reflects the weighted average sale price. Mr. Leung hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 9,114 | $7.03 | $64,071.42 |
DisclosureSEC source: 0001645113-20-000134 · wf-form4_159985533001922.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 20:17 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 100 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001645113-20-000126 · wf-form4_159925065083024.xml · derivative · entry 3 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,114 Underlying: Ordinary Shares · 100 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 20:17 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 100 | $85.00 | $8,500.00 |
DisclosureSEC source: 0001645113-20-000126 · wf-form4_159925065083024.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,045 F1 · price: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 20:17 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 100 | $7.03 | $703.00 |
DisclosureSEC source: 0001645113-20-000126 · wf-form4_159925065083024.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.